Literature DB >> 21790283

Mepolizumab in eosinophilic disorders.

J Pablo Abonia1, Philip E Putnam.   

Abstract

Mepolizumab (Bosatria(®), GlaxoSmithKline) is a biologic agent developed to treat asthma. It represents a humanized monoclonal antibody of IgG1 κ type, which targets human IL-5 and thus prevents its interaction with the α-chain of the IL-5 receptor. To date, it has not been approved for use in any eosinophil-related disorder; however, several studies have suggested some therapeutic benefit across a spectrum of eosinophil-related disorders. This article evaluates the currently available preclinical and clinical studies, and the impact of mepolizumab against a variety of eosinophilic disorders.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21790283      PMCID： PMC3201786          DOI： 10.1586/eci.11.27

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN： 1744-666X            Impact factor:   4.473


  62 in total

1.  Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys.

Authors:  P Zia-Amirhosseini; E Minthorn; L J Benincosa; T K Hart; C S Hottenstein; L A Tobia; C B Davis
Journal:  J Pharmacol Exp Ther       Date:  1999-12       Impact factor: 4.030

Review 2.  Interleukin-5, eosinophils, and disease.

Authors:  C J Sanderson
Journal:  Blood       Date:  1992-06-15       Impact factor: 22.113

3.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

Authors:  M J Leckie; A ten Brinke; J Khan; Z Diamant; B J O'Connor; C M Walls; A K Mathur; H C Cowley; K F Chung; R Djukanovic; T T Hansel; S T Holgate; P J Sterk; P J Barnes
Journal:  Lancet       Date:  2000 Dec 23-30       Impact factor: 79.321

4.  An etiological role for aeroallergens and eosinophils in experimental esophagitis.

Authors:  A Mishra; S P Hogan; E B Brandt; M E Rothenberg
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

Review 5.  A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.

Authors:  William W Busse; Johannes Ring; Johannes Huss-Marp; Jean-Emmanuel Kahn
Journal:  J Allergy Clin Immunol       Date:  2010-04       Impact factor: 10.793

6.  Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.

Authors:  T K Hart; R M Cook; P Zia-Amirhosseini; E Minthorn; T S Sellers; B E Maleeff; S Eustis; L W Schwartz; P Tsui; E R Appelbaum; E C Martin; P J Bugelski; D J Herzyk
Journal:  J Allergy Clin Immunol       Date:  2001-08       Impact factor: 10.793

7.  The spectrum of pediatric eosinophilic esophagitis beyond infancy: a clinical series of 30 children.

Authors:  S R Orenstein; T M Shalaby; C Di Lorenzo; P E Putnam; L Sigurdsson; H Mousa; S A Kocoshis
Journal:  Am J Gastroenterol       Date:  2000-06       Impact factor: 10.864

8.  Treatment of hypereosinophilic syndrome with imatinib mesilate.

Authors:  Gerald J Gleich; Kristin M Leiferman; Animesh Pardanani; Ayalew Tefferi; Joseph H Butterfield
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

9.  Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.

Authors:  Patricia Ault; Jorge Cortes; Charles Koller; Elizabeth S Kaled; Hagop Kantarjian
Journal:  Leuk Res       Date:  2002-09       Impact factor: 3.156

10.  A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5.

Authors:  M V Milburn; A M Hassell; M H Lambert; S R Jordan; A E Proudfoot; P Graber; T N Wells
Journal:  Nature       Date:  1993-05-13       Impact factor: 49.962
View more
  22 in total

Review 1.  The Role of Type 2 Inflammation in the Pathogenesis of Asthma Exacerbations.

Authors:  Eleanor M Dunican; John V Fahy
Journal:  Ann Am Thorac Soc       Date:  2015-11

Review 2.  Innate and adaptive immune responses in asthma.

Authors:  Stephen T Holgate
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

Review 3.  Overlapping Effects of New Monoclonal Antibodies for Severe Asthma.

Authors:  Christian Domingo
Journal:  Drugs       Date:  2017-10       Impact factor: 9.546

4.  A Novel Orally Available Asthma Drug Candidate That Reduces Smooth Muscle Constriction and Inflammation by Targeting GABAA Receptors in the Lung.

Authors:  Gloria S Forkuo; Amanda N Nieman; Revathi Kodali; Nicolas M Zahn; Guanguan Li; M S Rashid Roni; Michael Rajesh Stephen; Ted W Harris; Rajwana Jahan; Margaret L Guthrie; Olivia B Yu; Janet L Fisher; Gene T Yocum; Charles W Emala; Douglas A Steeber; Douglas C Stafford; James M Cook; Leggy A Arnold
Journal:  Mol Pharm       Date:  2018-04-02       Impact factor: 4.939

5.  MIDD0301 - A first-in-class anti-inflammatory asthma drug targets GABAA receptors without causing systemic immune suppression.

Authors:  Nicolas M Zahn; Alec T Huber; Brandon N Mikulsky; Mae E Stepanski; Alexander S Kehoe; Guanguan Li; Melissa Schussman; Mohammed S Rashid Roni; Revathi Kodali; James M Cook; Douglas C Stafford; Douglas A Steeber; Leggy A Arnold
Journal:  Basic Clin Pharmacol Toxicol       Date:  2019-02-21       Impact factor: 4.080

Review 6.  Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy.

Authors:  B Maisch; S Pankuweit
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

Review 7.  Changing roles of eosinophils in health and disease.

Authors:  Glenn T Furuta; F Dan Atkins; Nancy A Lee; James J Lee
Journal:  Ann Allergy Asthma Immunol       Date:  2014-05-01       Impact factor: 6.347

8.  Pediatric Eosinophilic Esophagitis Symptom Scores (PEESS v2.0) identify histologic and molecular correlates of the key clinical features of disease.

Authors:  Lisa J Martin; James P Franciosi; Margaret H Collins; J Pablo Abonia; James J Lee; Kevin A Hommel; James W Varni; J Tommie Grotjan; Michael Eby; Hua He; Keith Marsolo; Philip E Putnam; Jose M Garza; Ajay Kaul; Ting Wen; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2015-06       Impact factor: 10.793

9.  Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment.

Authors:  Rinat Zaynagetdinov; Taylor P Sherrill; Linda A Gleaves; Allyson G McLoed; Jamie A Saxon; Arun C Habermann; Linda Connelly; Daniel Dulek; R Stokes Peebles; Barbara Fingleton; Fiona E Yull; Georgios T Stathopoulos; Timothy S Blackwell
Journal:  Cancer Res       Date:  2015-02-17       Impact factor: 12.701

Review 10.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.